Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 297, Issue 2, 2009, Pages

  Villeneuve, C ^a,b   Caudrillier, A ^a,b   Ordener, C ^a,b   Pizzinat, N ^a,b   Parini, A ^a,b   Mialet Perez, J ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

5 hydroxytryptamine; 5 hydroxytryptamine 2A; Hypertrophy; Monoamine oxidase type A

Indexed keywords

1 [5 (2 THIENYLMETHOXY) 3 INDOLYL] 2 PROPANAMINE; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ALPHA ACTIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; CALCINEURIN; CALCIUM; KETANSERIN; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE; N (2 AMINOETHYL) 5 (3 FLUOROPHENYL) 4 THIAZOLECARBOXAMIDE; NUCLEAR FACTOR; PARGYLINE; REACTIVE OXYGEN METABOLITE; SEROTONIN; SEROTONIN 2 RECEPTOR; SEROTONIN 2A ANTAGONIST; TRANSCRIPTION FACTOR NFAT; TRITIUM; VOLINANSERIN;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART HYPERTROPHY; HEART MUSCLE CELL; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE;

ANIMALS; CALCINEURIN; CARDIOMEGALY; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; LEUCINE; MAP KINASE SIGNALING SYSTEM; MONOAMINE OXIDASE; MYOCYTES, CARDIAC; NFATC TRANSCRIPTION FACTORS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTOR, SEROTONIN, 5-HT2A; RNA, MESSENGER; SEROTONIN; SEROTONIN AGENTS; TRITIUM; VENTRICULAR REMODELING;

EID: 68049115746     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00345.2009     Document Type: Article

References (24)

1. Barry SP, Davidson SM, Townsend PA. Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol 40: 2023-2039, 2008.
2. Bianchi P, Kunduzova O, Masini E, Cambon C, Bani D, Raimondi L, Seguelas MH, Nistri S, Colucci W, Leducq N, Parini A. Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. Circulation 112: 3297-3305, 2005. (Pubitemid 43739375)
3. Bianchi P, Pimentel DR, Murphy MP, Colucci WS, Parini A. A new hypertrophic mechanism of serotonin in cardiac myocytes: receptor-independent ROS generation. FASEB J 19: 641-643, 2005. (Pubitemid 40471271)
4. Brattelid T, Qvigstad E, Birkeland JA, Swift F, Bekkevold SV, Krobert KA, Sejersted OM, Skomedal T, Osnes JB, Levy FO, Sjaastad I. Serotonin responsiveness through 5-HT2A and 5-HT4 receptors is differentially regulated in hypertrophic and failing rat cardiac ventricle. J Mol Cell Cardiol 43: 767-779, 2007. (Pubitemid 350166381)
5. Bush E, Fielitz J, Melvin L, Martinez-Arnold M, McKinsey TA, Plichta R, Olson EN. A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. Proc Natl Acad Sci USA 101: 2870-2875, 2004. (Pubitemid 38327703)
6. Cerbai E, Barbieri M, Li Q, Mugelli A. Ionic basis of action potential prolongation of hypertrophied cardiac myocytes isolated from hypertensive rats of different ages. Cardiovasc Res 28: 1180-1187, 1994. (Pubitemid 24264724)
7. Chandra M, Gupta V, Johri AK, Misra R, Kumar A, Gujrati V, Shanker K. Serotonergic mechanisms in heart failure. Indian Heart J 46: 153-156, 1994.
8. Cobo C, Alcocer L, Chavez A. Effects of ketanserin on left ventricular hypertrophy in hypertensive patients. Cardiovasc Drugs Ther 4, Suppl 1: 73-76, 1990. (Pubitemid 20106954)
9. Gustafsson BI, Tommeras K, Nordrum I, Loennechen JP, Brunsvik A, Solligard E, Fossmark R, Bakke I, Syversen U, Waldum H. Long-term serotonin administration induces heart valve disease in rats. Circulation 111: 1517-1522, 2005. (Pubitemid 40470647)
10. Jaffre F, Bonnin P, Callebert J, Debbabi H, Setola V, Doly S, Monassier L, Mettauer B, Blaxall BC, Launay JM, Maroteaux L. Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res 104: 113-123, 2009.
11. Jaffre F, Callebert J, Sarre A, Etienne N, Nebigil CG, Launay JM, Maroteaux L, Monassier L. Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts. Circulation 110: 969-974, 2004. (Pubitemid 39128622)
12. Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, Sarov-Blat L, Steplewski K, Aiyar N, Douglas SA. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 370: 238-250, 2004. (Pubitemid 40063823)
13. Keys JR, Greene EA, Koch WJ, Eckhart AD. Gq-coupled receptor agonists mediate cardiac hypertrophy via the vasculature. Hypertension 40: 660-666, 2002.
14. Kong SW, Bodyak N, Yue P, Liu Z, Brown J, Izumo S, Kang PM. Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats. Physiol Genomics 21: 34-42, 2005. (Pubitemid 40898463)
15. Lairez O, Calise D, Bianchi P, Ordener C, Spreux-Varoquaux O, Guilbeau-Frugier C, Escourrou G, Seif I, Roncalli J, Pizzinat N, Galinier M, Parini A, Mialet-Perez J. Genetic deletion of MAO-A promotes serotonin-dependent ventricular hypertrophy by pressure overload. J Mol Cell Cardiol 46: 587-595, 2009.
16. Maurel A, Hernandez C, Kunduzova O, Bompart G, Cambon C, Parini A, Frances B. Age-dependent increase in hydrogen peroxide production by cardiac monoamine oxidase A in rats. Am J Physiol Heart Circ Physiol 284: H1460-H1467, 2003. (Pubitemid 36348611)
17. Nigmatullina RR, Kirillova VV, Jourjikiya RK, Mukhamedyarov MA, Kudrin VS, Klodt PM, Palotas A. Disrupted serotonergic and sympathoadrenal systems in patients with chronic heart failure may serve as new therapeutic targets and novel biomarkers to assess severity, progression and response to treatment. Cardiology 113: 277-286, 2009.
18. Paradis P, MacLellan WR, Belaguli NS, Schwartz RJ, Schneider MD. Serum response factor mediates AP-1-dependent induction of the skeletal alpha-actin promoter in ventricular myocytes. J Biol Chem 271: 10827-10833, 1996. (Pubitemid 26149902)
19. Pchejetski D, Kunduzova O, Dayon A, Calise D, Seguelas MH, Leducq N, Seif I, Parini A, Cuvillier O. Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ Res 100: 41-49, 2007. (Pubitemid 46066772)
20. Qvigstad E, Sjaastad I, Brattelid T, Nunn C, Swift F, Birkeland JA, Krobert KA, Andersen GO, Sejersted OM, Osnes JB, Levy FO, Skomedal T. Dual serotonergic regulation of ventricular contractile force through 5-HT2A and 5-HT4 receptors induced in the acute failing heart. Circ Res 97: 268-276, 2005. (Pubitemid 41105453)
21. Sanna B, Bueno OF, Dai YS, Wilkins BJ, Molkentin JD. Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth. Mol Cell Biol 25: 865-878, 2005. (Pubitemid 40165796)
22. Stuck BJ, Lenski M, Bohm M, Laufs U. Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase. J Biol Chem 283: 32562-32569, 2008.
23. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94: 110-118, 2004. (Pubitemid 38064105)
24. Yabanoglu S, Akkiki M, Seguelas MH, Mialet-Perez J, Parini A, Pizzinat N. Platelet derived serotonin drives the activation of rat cardiac fibroblasts by 5-HT2A receptors. J Mol Cell Cardiol 2009.